Vol 25, No 1 (2022)

Date published: 2022-01-31

Table of Contents

open access

Editorial

Editorial Note

Grzegorz Kamiński

Editorial

Nucl. Med. Rev 2022;25(1).
Original articles

Assessing the correlation between FDG PET findings of IDC breast carcinoma and histopathology of coexisting ductal carcinoma in-situ

Ismet Sarikaya, Ali Sarikaya, Ahmed N. Albatineh, Ebru Tastekin, Yavuz Atakan Sezer

Research paper

Pubmed: 35137931
Nucl. Med. Rev 2022;25(1):6-11.

Degree of agreement between dacryoscintigraphy and dacryocystography examinations results in primary acquired nasolacrimal duct obstruction

Elyas Aditya, Yunia Irawati, Benny Zulkarnaien, Joedo Prihartono

Research paper

Pubmed: 35137932
Nucl. Med. Rev 2022;25(1):12-17.

Relationship between cerebral blood flow reduction patterns on scintigraphy and nonmotor symptoms in new-onset Lewy body disease

Yukinori Okada, Makoto Shiraishi, Koji Hori, Keiichro Yamaguchi, Yasuhiro Hasegawa

Research paper

Pubmed: 35137933
Nucl. Med. Rev 2022;25(1):18-24.

Detection of a second primary cancer in a 18F-fluorocholine PET/CT – multicentre retrospective analysis on a group of 1345 prostate cancer patients

Paulina Cegla, Katarzyna Scibisz-Dziedzic, Kamila Witkowska, Anna Kubiak, Ewa Wierzchoslawska, Witold Kycler, Beata Chrapko, Rafał Czepczyński

Research paper

Pubmed: 35137934
Nucl. Med. Rev 2022;25(1):25-30.

The efficacy of melatonin against radiotoxicity of iodine-131 and its response to treatment in hyperthyroid patients: a randomized controlled trial

Soudabe Alidadi, Ali Shabestani Monfared, Mehrangiz Amiri, Ebrahim Zabihi, Ehsan Assadollahi, Amir Gholami, Zoleika Moazezi, Zeinab Abedian

Research paper

Pubmed: 35137935
Nucl. Med. Rev 2022;25(1):31-36.

Optimal activity of [18F]FDG for Hodgkin lymphoma imaging performed on PET/CT camera with BGO crystals

Miroslaw Dziuk, Ewa Witkowska-Patena, Agnieszka Gizewska, Andrzej Mazurek, Anna Pieczonka, Magdalena Koza, Marina Gerszewska, Zbigniew Podgajny, Marta Chojnowska

Research paper

Pubmed: 35137937
Nucl. Med. Rev 2022;25(1):47-53.

Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm

Barbara Bober, Marek Saracyn, Arkadiusz Lubas, Maciej Kolodziej, Dorota Brodowska-Kania, Waldemar Kapusta, Grzegorz Kaminski

Research paper

Pubmed: 35137938
Nucl. Med. Rev 2022;25(1):54-61.
Clinical vignette

Efficacy of long-term ultrasonography in follow-up of patients with papillary thyroid carcinoma: a case of neck metastasis developed 19 years following primary treatment

Vlatka Jozanovic, Sanja Kusacic Kuna, Marija Despot, Tatjana Samardzic, Drazen Huic

Clinical vignette

Pubmed: 35137939
Nucl. Med. Rev 2022;25(1):62-63.

Different glucose metabolism behavior relating to histotypes in synchronous breast cancers evaluated by [18F]FDG PET-CT

Pietro Bellini, Domenico Albano, Francesco Dondi, Francesco Bertagna, Raffaele Giubbini

Clinical vignette

Pubmed: 35137940
Nucl. Med. Rev 2022;25(1):64-65.

Rare osteoarticular complications on [18F]FDG-PET/CT — following intravesical BCG immunotherapy for bladder cancer

Jan-Henning Schierz, Anke McLeod, Farzana Ali

Clinical vignette

Pubmed: 35137942
Nucl. Med. Rev 2022;25(1):68-69.

Hybrid bone SPECT/CT reveals spleen calcification in sickle cell mutation and beta-thalassemia

Konstantinos Sakellariou, Sofia Charalampidou, Andreas Fotopoulos, Chrissa Sioka

Clinical vignette

Pubmed: 35137943
Nucl. Med. Rev 2022;25(1):70-71.



Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl